1. Home
  2. CVKD

as 11-21-2024 3:33pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Founded: 2022 Country:
United States
United States
Employees: N/A City: PONTE VEDRA
Market Cap: 26.3M IPO Year: 2023
Target Price: $46.00 AVG Volume (30 days): 72.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -7.06 EPS Growth: N/A
52 Week Low/High: $5.40 - $32.55 Next Earning Date: 11-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

CVKD Daily Stock ML Predictions

Share on Social Networks: